Sustained release of antiinfectives

Details Sustained release of antiinfectives Sustained release of antiinfectives

2003-10-29

2009-06-09

Kishore, Gollamudi S (Department: 1612)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

Reexamination Certificate

active

07544369

ABSTRACT:
Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.

REFERENCES:
patent: 4372949 (1983-02-01), Kodama et al.
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4396630 (1983-08-01), Riedl et al.
patent: 4451447 (1984-05-01), Kaplan et al.
patent: 4693999 (1987-09-01), Axelsson et al.
patent: 4767874 (1988-08-01), Shima et al.
patent: 4895452 (1990-01-01), Yiournas et al.
patent: 4895719 (1990-01-01), Radhakrishnan et al.
patent: 4897384 (1990-01-01), Janoff et al.
patent: 4933121 (1990-06-01), Law et al.
patent: 4952405 (1990-08-01), Yau-Young
patent: 4975282 (1990-12-01), Cullis et al.
patent: 4981692 (1991-01-01), Popescu et al.
patent: 5000958 (1991-03-01), Fountain et al.
patent: 5006343 (1991-04-01), Benson et al.
patent: 5023087 (1991-06-01), Yau-Young
patent: 5030453 (1991-07-01), Lenk et al.
patent: 5049388 (1991-09-01), Knight et al.
patent: 5049389 (1991-09-01), Radhakrishnan
patent: 5059591 (1991-10-01), Janoff et al.
patent: 5077056 (1991-12-01), Bally et al.
patent: 5169637 (1992-12-01), Lenk et al.
patent: 5178876 (1993-01-01), Khokhar et al.
patent: 5211955 (1993-05-01), Legros et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5269979 (1993-12-01), Fountain
patent: 5279833 (1994-01-01), Rose
patent: 5320906 (1994-06-01), Eley et al.
patent: 5334761 (1994-08-01), Gebeyehu et al.
patent: 5409704 (1995-04-01), Bally et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5540936 (1996-07-01), Coe et al.
patent: 5543152 (1996-08-01), Webb et al.
patent: 5569464 (1996-10-01), Endo et al.
patent: 5616334 (1997-04-01), Janoff et al.
patent: 5641662 (1997-06-01), Debs
patent: 5643599 (1997-07-01), Lee et al.
patent: 5662929 (1997-09-01), Lagace et al.
patent: 5665383 (1997-09-01), Grinstaff et al.
patent: 5723147 (1998-03-01), Kim et al.
patent: 5741516 (1998-04-01), Webb et al.
patent: 5753613 (1998-05-01), Ansell et al.
patent: 5756120 (1998-05-01), Hersch et al.
patent: 5756353 (1998-05-01), Debs
patent: 5759571 (1998-06-01), Hersch et al.
patent: 5766627 (1998-06-01), Sankaram et al.
patent: 5795589 (1998-08-01), Mayer et al.
patent: 5820848 (1998-10-01), Boni et al.
patent: 5843473 (1998-12-01), Woodle et al.
patent: 5849490 (1998-12-01), Schonwetter et al.
patent: 5875776 (1999-03-01), Vaghefi
patent: 5945122 (1999-08-01), Abra et al.
patent: 6045828 (2000-04-01), Bystrom et al.
patent: 6051251 (2000-04-01), Zalipsky et al.
patent: 6090407 (2000-07-01), Knight et al.
patent: 6147060 (2000-11-01), Zasloff et al.
patent: 6211162 (2001-04-01), Dale et al.
patent: 6221388 (2001-04-01), Hersch et al.
patent: 6352996 (2002-03-01), Cao et al.
patent: 6419901 (2002-07-01), Placke et al.
patent: 6440393 (2002-08-01), Waldrep et al.
patent: 6451784 (2002-09-01), Placke et al.
patent: 6497901 (2002-12-01), Royer
patent: 6511676 (2003-01-01), Boulikas
patent: 6599912 (2003-07-01), Au et al.
patent: 6843942 (2005-01-01), Katinger et al.
patent: 2001/0006660 (2001-07-01), Lagace et al.
patent: 2002/0187105 (2002-12-01), Zou et al.
patent: 2003/0059375 (2003-03-01), Perez-Soler et al.
patent: 2003/0118636 (2003-06-01), Friesen et al.
patent: 2005/0019926 (2005-01-01), Gonda et al.
patent: 0069307 (1983-01-01), None
patent: 2145107 (1985-03-01), None
patent: WO-86/06959 (1986-12-01), None
patent: WO-91/16882 (1991-11-01), None
patent: WO-93/12240 (1993-06-01), None
patent: 94/12155 (1994-06-01), None
patent: WO-94/12156 (1994-06-01), None
patent: WO-96/19199 (1996-06-01), None
patent: WO-96/19972 (1996-07-01), None
patent: WO-99/65466 (1999-12-01), None
patent: WO-00/27359 (2000-05-01), None
patent: WO-00/29103 (2000-05-01), None
patent: WO-03/075889 (2003-09-01), None
Deol et al in Biochimica et Biophysica Acta, 1334, pp. 161-172, (1997).
International Search Report, PCT/US03/34240 mailed on Jul. 12, 2005.
Niven, Ralph et al., Nebulization of Liposomes. I. Effects of Lipid Composition, Report, pp. 1127-1133.
Katare, O.P., et al., Enhanced in vivo Performance of Liposomal Indomethacin Derived From Effervescent Granule Based Proliposomes, J. Microencapsulation, 1995, vol. 12, No. 5, pp. 487-493.
Petkowicz, Jozefa, et al., Hypoglycemic Effect of Liposome-Entrapped Insulin Administered by Various Routes into Normal Rats, Pol. J. Pharmacol. Pharm., 1989, 41, pp. 299-304.
Comis, “Carboplatin in the Treatment of Non-Small Cell Lung Cancer: a Review,”Oncology, 1993 Nov.; 50 (2): 37-41. (Abstract).
A.Bargoni, R. Cavalli, G.P. Zara, A. Fundaro, O. Caputo, M.R. Gasco (2001) Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II—Tissue distribution. Pharmacological Research 43(5):497-502.
J. Lagace, M. Dubreuil, S. Montplaisir (1991) Liposome-encapsulated antibiotics: preparation, drug release and antimicrobial activity againstPseudomona aeruginosa. Journal Microencapsulation 8(1): 53-61.
L.S. Ramsammy, G.J. Kaloyanides (1988) The effect of gentamicin on the biophysical properties of phosphatidic acid liposomes is influenced by the O−C=O group of the lipid. Biochemistry 27:8249-8254.
C. Dees, R.D. Schultz (1990) The mechanism of enhanced intraphagocytic killing of bacteria by liposomes containing antibiotics. Veterinary Immunology and Immunopathology 24: 135-146.
C. Beaulac, S. Sachetelli, J. Lagace (1999) Aerolization of low phase transition temperature liposomal tobramycin as dry powder in an animal model of chronic pulmonary infection caused byPseudomonas aeruginosa. Journal Drug Targeting 7(1): 33-41.
J.F. Marier, J.L. Brazier, J. Lavigne, M.P. Ducharme (2003) Liposomal tobramycin against pulmonary infections ofPseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. Journal Antimicrobial Chemotherapy 52: 247-252.
E.A. Poyner, H.O. Alpar, M.R.W. Brown (1993) Preparation, properties and the effects of free and liposomal tobramycin on siderophore production byPseudomonas aeruginosa. Journal Antimicrobial Chemotherapy 34: 43-52.
A. Omri, M. Ravaoarinoro, M. Poisson (1995) Incorporation, release and in vitro antibacterial activity of liposomal aminoglycosides againstPseudomonas aeruginosa. Journal Antimicrobial Chemotherapy 36: 631-639.
C. Beaulac, S. Clement-Major, J. Hawari, J. Lagace (1997) In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. Journal Microencapsulation 14(3): 335-348.
P. Demaeyer, E.M. Akodad, E. Gravet, P. Schietecat, J.P. van Vooren, A. Drowart, J.C. Yernault, F.J. Legros (1993) Disposition of liposomal gentamicin following intrabronchial administration in rabbits. Journal Microencapsulation 10(1): 77-88.
M. Antos, E.A. Trafny, J. Gryzbowski (1995) Antibacterial activity of liposomal amikacin againstPseudomonas aeruginosain vitro. Pharmacological Research 32(½): 84-87.
R.M. Schiffelers, G. Storm, I.A.J.M. Bakker-Woudenberg (2001) Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models. International Journal Pharmaceutics 214: 103-105.
L.E. Bermudez, A.O. Yau-Young, J.-P. Lin, J. Cogger, L.S. Young (1999) Treatment of Disseminated Mycobacterium avium Complex Infection of Beige Mice with Liposome-Encapsulated Aminoglycosides. Journal Infect. Dis. 161: 1262-1268.
J.H. Zhang and J.B. Zhu (1999) A Novel Method to Prepare Liposomes Containing Amikacin. Journal Microencapsulation 16(4): 511-516.
S. Zeng, C. Hu, H. Wei, Y. Lu, Y. Zhang, J. Yang, G. Yun, W. Zou, B. Song (1993) Intravitreal Pharmacokinetics of Liposome-encapsulated Amikacin in a Rabbit Model. Opthamology 100: 1640-1644.
M.H. Cynamon, C.E. Swenson, G.S. Palmer, & R.S. Ginsberg (1989) Liposome-Encapsulated-Amikacin Therapy of Mycobacterium avium Complex Infection in G

Affiliated with

Also associated with

Rating

Sustained release of antiinfectives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sustained release of antiinfectives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release of antiinfectives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4071505